Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)

Today, Galmed Pharmaceuticals (NASDAQ:GLMD) stock received an upgrade by Maxim Group from Hold to Buy with a price target of $14.00.

Some recent analyst ratings include

• 3/15/2018-Maxim Group Upgrade from a “Hold ” rating to a ” Buy” rating.
• 11/15/2017-Roth Capital initiated coverage with a Buy rating.
• 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.

Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
Shares of Galmed Pharmaceuticals closed the previous trading session at with 6.909999847412109 shares trading hands.